November 2, 2017
Re: Canadian Blood Services Request For Proposals (RFP) Announcement for Plasma Protein Products 2018-2021
CBS has announced the results for the RFP for plasma products, both for the fractionation of CBS plasma and the commercial supply of immune globulin (both IVIG and SubQ). These contracts are for a 3 year period starting April 1st 2018, with 2 optional 1 year extensions.
There is no change that affects patients to the fraction contracts with CBS. Grifols and CSL Behring will continue to be the two fractionators of Canadian plasma collected by CBS. Of the plasma collected, Canadian products for PI patients made will be: IVIGNex and Privigen.
Gammunex (Grifols, 10%) will continue to be available. Gammagard (Shire, 20%) will be added to the portfolio. Panzyga (Octapharma) will be phased out.
Cuvitru (Shire, 20%) will be added to the portfolio and Hizentra (CSL Behring, 20%) will be phased out.
We are aware that this announcement by CBS affects a large portion of the PI community in Canada. Transitions are not expected to take place for several months, and the exact details have yet to be decided on. We are currently in discussions with CBS, the suppliers, and the healthcare providers to assist to make these transitions as smooth as possible. If you have any concerns, please contact your healthcare provider or firstname.lastname@example.org
CIPO National Board